Status | Study |
RECRUITING |
Study Name: A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT Condition: Pigmented Villonodular Synovitis Date: 2022-04-22 Interventions: A fully human monoclonal immunoglobulin (IgG2) directed against c-fms |
Recruiting |
Study Name: Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project Condition: Giant Cell Tumors Date: 2016-10-24 |
Recruiting |
Study Name: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor Condition: Solid Tumors Tenosynovial Giant Cell Tumor Date: 2016-01-29 Interventions: Drug: PLX73086 |
Recruiting |
Study Name: Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Condition: Pigmented Villonodular Synovitis Tenosyno Date: 2015-06-01 Interventions: Drug: FPA008 FPA008 will be administered by IV infusion over approximately 30 minutes every 2 weeks |
Active, not recruiting |
Study Name: PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Condition: Pigmented Villonodular Synovitis Giant Cell Tumors of the Tendo Date: 2015-02-19 Interventions: Drug: PLX3397 capsule Each cap |
Recruiting |
Study Name: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Condition: Solid Tumor Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutation Date: 2013-03-01 Interventions: Drug: PLX7486 TsOH PLX7486 TsOH capsules, 50mg |
Recruiting |
Study Name: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS) Condition: Pigmented Villonodular Synovitis PVNS Date: 2012-03-08 Interventions: Drug: MCS110 Patients will rec |
Completed |
Study Name: Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Condition: Pigmented Villonodular Synovitis Date: 2010-12-15 Interventions: Drug: Tasigna The study drug is nilotinib (Tasigna®). |
Active, not recruiting |
Study Name: Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Condition: Pigmented Villonodular Synovitis Diffuse-type Giant Cell Tumor Date: 2010-09-21 Interventions: Drug: nilotinib Taken orally twice daily |